Given that IL-8 has been implicated in tumor resistance to a broad number of cancer therapies, we evaluated whether blockade of IL-8 signaling via inhibition of the CXCR1/2 receptors may improve the response of HPV-negative HNSCC to various chemotherapies. The gene discussed is CXCR1; the disease is neoplasm.